Evaluation of the utility of manual thromboaspiration for coronary blood flow recovery in patients with ST elevation myocardial infarction

Abstract

Chronic kidney disease (CKD) has a high prevalence in patients with some cardiovascular diseases, as well as in the general population. In many large-scale studies have shown the value of CKD as an independent predictor of the risk of cardiovascular complications and death. At the moment, a number of studies carried out, during which studied the efficacy and safety of individual statins in patients with CKD. A large number of studies conducted with atorvastatin possible to evaluate the safety of the latest high in patients with CKD is not only to reduce the decrease in glomerular filtration rate (GFR), but in some cases, to increase the value of this indicator. The results of a post hoc analysis of large randomized clinical trials (RCTs) have demonstrated the possibility of atorvastatin to reduce the risk of adverse clinical outcomes in patients with various cardiovascular diseases and CKD.